%0 Journal Article
%A Thielmann, Carl Maximilian
%A Seier, Johanna Andrea
%A Schielke, Lisa
%A Albrecht, Lea Jessica
%A Zimmer, Lisa
%A Livingstone, Elisabeth
%A Zaremba, Anne
%A Lodde, Georg
%A Dissemond, Joachim
%A Sondermann, Wiebke
%A Krefting, Frederik
%A Tasdogan, Alpaslan
%A Roesch, Alexander
%A Hadaschik, Eva
%A Rambow, Florian
%A Griewank, Klaus
%A Ugurel, Selma
%A Schadendorf, Dirk
%A Placke, Jan-Malte
%T Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients.
%J Frontiers in immunology
%V 16
%@ 1664-3224
%C Lausanne
%I Frontiers Media
%M DKFZ-2026-00028
%P 1727312
%D 2025
%X Checkpoint inhibition induced immune-related adverse events (irAE) may be steroid-dependent or steroid-refractory and are associated with increased morbidity, mortality and potentially compromised anti-tumor immunity. Extracorporeal photopheresis (ECP) has emerged as an alternative for salvage therapy, however, evidence remains scarce.This monocenter retrospective study included patients with either irColitis or irHepatitis, who received ECP after failure or dependence on high-dose corticosteroids + infliximab/vedolizumab or mycophenolate mofetil/tacrolimus. Clinical activity was quantified at least weekly (stool frequency for colitis; AST/ALT for hepatitis) and primary endpoint was change in irAE activity over time. Secondary analyses included steroid-sparing, overall safety, and melanoma-specific outcomes. Spearman's correlation assessed irAE severity reduction.Six patients were included in this study (irColitis n = 4; irHepatitis n = 2; CTCAE ≥ 3). Extracorporeal photopheresis was started after initial therapy with corticosteroids and immunosuppression was not successful. All ECP cycles included two consecutive treatment days. irAE activity declined promptly after ECP across patients: irColitis showed strong negative correlation with time since ECP (rs range -0.88 to -0.97); irHepatitis displayed parallel ALT/AST declines (rs ≥ -0.92). Corticosteroids were tapered following ECP start with a median corticosteroid reduction across all patients to 25
%K Humans
%K Photopheresis: methods
%K Male
%K Female
%K Middle Aged
%K Melanoma: drug therapy
%K Melanoma: immunology
%K Melanoma: therapy
%K Aged
%K Retrospective Studies
%K Immune Checkpoint Inhibitors: adverse effects
%K Immune Checkpoint Inhibitors: therapeutic use
%K Treatment Outcome
%K Programmed Cell Death 1 Receptor: antagonists & inhibitors
%K Programmed Cell Death 1 Receptor: immunology
%K Adult
%K extracorporeal photopheresis (Other)
%K immune checkpoint inhibitors (Other)
%K immune related colitis (Other)
%K immune related hepatitis (Other)
%K melanoma (Other)
%K Immune Checkpoint Inhibitors (NLM Chemicals)
%K Programmed Cell Death 1 Receptor (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41476990
%2 pmc:PMC12748251
%R 10.3389/fimmu.2025.1727312
%U https://inrepo02.dkfz.de/record/307523